Lack of reproducibility in drug discovery has thrown the industry into crisis, scientists from Molecule and Arctoris claim, and suggest their discovery platform answers this challenge.
Sanofi will use AbSci’s platform to further optimize two of its in-house proteins – and will partner with other companies to accelerate timelines and reduce costs.
“Small molecule products should be packaged at the location where they are produced,” says Roche, which is laying-off 235 jobs at a packaging plant in Switzerland.
The new Changzhou, China-based site adds transition metal catalyst-screening technology to STA’s small molecule process development and manufacturing platform.
Boehringer Ingelheim and Philogen have signed a multi-target research agreement to discover and optimize new small molecule therapeutics for unmet medical needs.
Sanofi says it will demolish a pilot plant in Montpellier that has been left idle since its completion in 2011, citing its evolving biologics-focused portfolio.
AstraZeneca has partnered with Bicycle Therapeutics in a potential $1bn deal to develop a new class of small molecules which have antibody-like properties.
Closure of its Benicar intermediates plant was prompted by impending US patent loss and a decision to focus on large molecule drugs says Daiichi Sankyo.
Unchained Labs has acquired Freeslate, a provider of high-throughput solutions for biologics formulation development and small molecule chemistry – marking the company’s 4th acquisition in 12 months.
An operational rejig at DPT Laboratories, an expansion at UDG, and a synthesis and toxicology testing contract win for Dalton – welcome to Outsourcing-Pharma’s CDMO round-up.
EMA guidance on process validation for drugmakers is the latest update in cGMP regulations to manage a pharma world shifting from chemical to biological processing, says NNE Pharmaplan.
PPD’s recently acquired biotech company X-Chem is launching a multi-target collaboration with Janssen Biotech. Financial terms of the deal were not disclosed.
PPD’s biotech company X-Chem has licensed a second drug discovery program to Bayer Pharma, which follows on a multi-target collaboration the companies established in 2012.
Eli Lilly is maintaining greater in-house control as manufacturing processes become more complex, whilst MSD is leveraging external over-capacity to fulfil its needs, the firms told Outsourcing-Pharma.com during a recent visit to Ireland.
AMRI says it intends to expand its API business to target both generics and more complex molecules after reporting record full year revenue from contract services.
Enteris has secured its first partnership to develop metabolic peptides for Nordic Bioscience using an oral delivery platform it says offers unparalleled bioavailability.
Charles River Laboratories has partnered with eCRO Target Health and Theorem Clinical Research to support the transfer and validation of assays supporting the CROs’ preclinical programs.
Anglo-German company Evotec is joining forces with Almirall to identify small molecule modulators of an ion channel target involved in respiratory diseases.
Sheffield Bio-Science takes on responsibility for global sales, distribution and development of Girus Life Sciences’ chemically defined Regocel supplements.
Lonza will shut down its API plant in Riverside, Pennsylvania, US by the end of the year as part of a plan to cut costs and shift small-molecule production to Asia.
Swiss healthcare services giant Lonza has withdrawn its offer for Canadian CMO Patheon, citing value considerations, rejection of the bid by JLL and the availability of alternatives.
US discovery chemistry contractor ChemBridge has made some of its most popular small molecule libraries available on-line through a partnership with preclinical data specialist Collaborative Drug Discovery (CDD).
You'll be unlikely to see them at your local cinema, but molecular
animations created using highly accurate information from X-ray
scattering images, will help explain how proteins and organic
molecules behave in a solution.
Anglo-German firm Evotec is taking its fragment-based drug
discovery (FBDD) services a step further with the launch today of a
new innovation centre for FBDD.
The Waters Corporation and Advion Biosciences have formed an
agreement in which the two companies intend to combine products and
offer life scientists enhanced capabilities.
British-based analysis services provider Intertek ASG has announced
it is expanding its analytical services to meet the growing demand
for macromolecule characterisation.
Cresset Biomolecular Discovery has launched a technology that
identifies the 3-dimensional bound conformation of hits and
potential drugs in a biological target, assisting scientists
involved in ion channel research.
Viscotek
launches its latest entry-level system for laboratories looking to
conduct characterisation of proteins, and other biomolecules,
allowing researchers to make a determination of absolute Molecular
Weight, a traditionally...
Global supplier of scientific instruments, Varian, have launched
its first premium shielded vertical high-resolution superconducting
magnets designed to reduce stray magnetic fields by up to fivefold
(in volume). Pharmaceutical and...
In the US, the National Institutes of Health has awarded $88.9
million in grants to nine institutions over three years to
establish a collaborative research network that will use high-tech
screening methods to identify small molecules...
Wyatt Technology is set to offer its first integrated solution for
batch dynamic light scattering, which are amongst a batch of
products set to bring improved high throughput screening and better
understanding of the physical attributes...
Applied Biosystems has launched two new mass spectrometers, which
extend the firm's existing product line providing improved
performance for proteomics and small molecule applications.
A novel lead-finding, series-switching technology, which can
accelerate selection of leads for targets based on molecular fields
rather than molecular structure, has been launched.
Scientists have determined the precise molecular structure of a
potential new target for treating prostate cancer, a disease driven
in part by abnormal testosterone activity, which affects one in six
American men.
Codexis has appointed a new head of biocatalysis and chemical
development, shoring up its expertise in what is a small but
fast-growing area of the catalysts market.
Bionanotechnology company Bioforce hasreached an agreement to field
test its transformational molecular printer, NanoArrayer, at the
Oak Ridge National Laboratory in the US, writes Wai Lang
Chu.
Sigma-Aldrich has negotiated an exclusive contract to distribute a
range of catalysts that are used in pharmaceutical discovery and
fine chemical production.
German pharmaceutical company Boehringer Ingelheim has signed a
long-term agreement with software company MDL Information Systems
to use its software technology for managing and deploying chemical
information systems.